Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStéphane MorissetCentre Léon BérardMSMarie SébertInsermGRGaspar Aspas RequenaUniversité de Montpellier

Discussion

Loading...

Member takes

Implication

Retrospective study shows improved response rates in acute myeloid leukemia patients using azacitidine, suggesting benefits of combination therapy.

Key Points

  • Ivosidenib with azacitidine shows a higher response rate in acute myeloid leukemia compared to monotherapy.
  • Response rates were higher in patients treated with azacitidine alongside ivosidenib, enhancing treatment outcomes.
  • Retrospective study included patients treated under a compassionate use program, analyzing their response and toxicity.
  • Study highlights real-life effectiveness of ivosidenib and azacitidine, supporting combination therapy approaches in practice.

Cite This Study

Morisset et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3achttps://doi.org/10.1182/blood-2025-1658
View Full Paper
Ask AI
Bookmark
Share